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Interleukin-18 (IL-18) is a pleiotropic pro-inflammatory cytokine belonging to
the IL-1 superfamily. IL-18 plays an important role in host innate and acquired
immune defense, with its activity being modulated in vivo by its naturally
occurring antagonist IL-18 binding protein (IL-18BP). Recent crystal structures
of human IL-18 (hIL-18) in complex with its antagonist or cognate receptor(s)
have revealed a conserved binding interface on hIL-18 representing a promising
drug target. An important step in this process is obtaining crystals of apo hIL-18
or hIL-18 in complex with small-molecule inhibitors, preferably under low ionic
strength conditions. In this study, surface-entropy reduction (SER) and rational
protein design were employed to facilitate the crystallization of hIL-18. The
results provide an excellent platform for structure-based drug design.
1. Introduction
Interleukin-18 (IL-18) is a pleiotropic pro-inflammatory
cytokine belonging to the IL-1 superfamily (Dinarello,
1999a,b; Okamura et al., 1995). IL-18 plays an important role
in both innate and acquired immune responses by inducing
interferon- (IFN-) production from T lymphocytes and
macrophages, while also enhancing the cytotoxicity of natural
killer cells (Dinarello, 1999a). Increased levels of mature IL-18
have a direct correlation with the severity of certain auto-
immune diseases such as multiple sclerosis (MS), rheumatoid
arthritis (RA) and lupus (Boraschi & Dinarello, 2006).
IL-18 activity is modulated in vivo by a negative-feedback
mechanism involving a naturally occurring IL-18 inhibitor,
IL-18BP. As an immune-evasion strategy, homologs of
IL-18BPs are also encoded by many poxviruses such as
Molluscum contagiosum virus, orthopoxviruses such as
Variola virus (the causative agent of smallpox) and yata-
poxviruses such as Yaba-like disease virus (YLDV). The
recent crystal structures of hIL-18 in complex with Ectromelia
virus (ectv; Krumm et al., 2008) and YLDV (Krumm et al.,
2012) IL-18BP revealed a conserved mechanism of hIL-18
inhibition through direct competition for a common binding
site with the hIL-18 primary receptor (hIL-18R) domain 3
(D3; Tsutsumi et al., 2014; Wei et al., 2014).
From the IL-18BP studies, it was shown that the complex
interface between hIL-18 and IL-18BP is comprised of a
mixture of charged and hydrophobic residues, but is overall
predominantly hydrophobic in nature (Krumm et al., 2008).
The crystal structures revealed a pliable surface of hIL-18 that
undergoes an induced-fit mechanism upon binding IL-18BPs,
involving three ligand-binding sites (A, B and C) on hIL-18
(Krumm et al., 2008, 2012; Figs. 1a and 1b). Contained within
binding site A is a critical hIL-18 lysine residue (Lys53), which
when mutated to alanine displayed a greater than 100-fold and
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fourfold decrease in binding affinity for Variola virus IL-18BP
and hIL-18R, respectively (Meng et al., 2007), indicating that
binding site A on the hIL-18 surface is a ‘hot spot’ that is
critical not only for its interaction with viral IL-18BPs but also
for initial hIL-18–receptor complex formation. Additionally,
binding site C on the hIL-18 interface is another potential ‘hot
spot’ as it contains a conserved phenylalanine residue that has
been shown to be critical for complex formation with ortho-
poxviruses, Molluscum contagiosum virus (MCV) and human
IL-18BP (Esteban & Buller, 2004; Krumm et al., 2012; Xiang &
Moss, 2001a,b).
The recent crystal structures of binary and ternary
complexes of hIL-18 with its receptors have shown that IL-
18BP competes directly with the hIL-18R D3 domain for
binding hIL-18, overlapping the previously identified hIL-18
binding site II. Superposition of hIL-18 molecules from the
viral IL-18BP complexes and the ternary complex reveals few
conformational changes of the core -trefoil fold, which has an
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Figure 1
Surface-entropy reduction (SER) clusters on hIL-18. (a) Crystal structure of the ectvIL-18BP–hIL-18 complex (PDB entry 3f62; Krumm et al., 2008).
EctvIL-18BP is depicted as a ribbon diagram and is colored light yellow; hIL-18 is shown as a surface representation. Residues of ectvIL-18BP at the
interface are shown as sticks interacting with previously identified binding sites on hIL-18 colored as follows: site A, red; site B, orange; site C, cyan. The
remaining surface of hIL-18 is colored gray. (b) Crystal structure of hIL-18 from PDB entry 3f62 drawn as a cartoon representation and colored green;
ectvIL-18BP has been removed for clarity, revealing the opening of the hIL-18 -trefoil barrel. (c) Crystal structure of the IL-18 ternary complex shown
as a ribbon diagram with IL-18R in cyan, IL-18R in magenta and IL-18 in green (PDB entry 3wo4; Tsutsumi et al., 2014). The colored spheres in (b)
and (c) are the SER clusters: mutant I, red; mutant II, yellow; mutants III, IVand V, blue. Notice that the mutation sites are distant from the IL-18BP and
IL-18R D3 domain interfaces.
r.m.s. deviation of 0.5–0.6 Å, although several loops show a
significant deviation upon interacting with the hIL-18 recep-
tors. Notably different is the buried surface area (BSA) and
the number of residues involved in the interface between hIL-
18 and the hIL-18R D3 domain. Site II between hIL-18 and
the hIL-18RD3 domain is relatively small (603 Å2; Wei et al.,
2014) when compared with the viral complex interfaces (the
ectv and YLDV IL-18BP interfaces have BSAs of 1930 and
1957 Å2, respectively; Krumm et al., 2008, 2012). As observed
previously in the viral inhibitory complexes, Lys53 of binding
site A in hIL-18 adopts a conserved interaction at the binding
interface with the receptor. However, in comparison to the
hIL-18–hIL-18R D3 interface, the viral inhibitory proteins
contribute many more aromatic and hydrophobic residues to
hIL-18 binding, including the conserved phenylalanine of
IL-18BP at binding site C. Thus, the identified surface patches
on hIL-18 could therefore be further targeted for the design of
small-molecule inhibitors that would have the potential to
discriminate between IL-18R and IL-18BP binding in the
future.
Protein–protein interactions are associated with many
crucial biological processes such as signal transduction, cell
adhesion, cellular proliferation, growth and differentiation,
while their malfunctions have been identified in numerous
pathological disease states. It is estimated that up to 650 000
interactions, termed the ‘interactome’, regulate biological
processes within the human cell (Stumpf et al., 2008). While
most small-molecule drugs currently on the market are either
competitive inhibitors of G protein-coupled receptors, nuclear
receptors, ion channels or enzymatic targets, a small but
increasing number of protein–protein inhibitors (PPIs) exist
that have shown successes in clinical trials (Tse et al., 2008;
Gandhi et al., 2011; Overington et al., 2006). PPI discovery
focuses on targeting binding clefts and ‘hot spots’ in protein-
interaction interfaces at which small molecules or fragments
can modulate their activity (Toogood, 2002).
Current therapeutic strategies for the treatment of patho-
genic autoimmune diseases is to target proteins involved in the
initiation event(s) of inflammation or ‘upstream’ events of the
innate immune response. These ‘upstream’ effector proteins
include cyclooxygenase 2 (Cox-2) and caspase-1 (interleukin-
1 converting enzyme; ICE) which respond to nonsteroidal
anti-inflammatory drugs (NSAIDs) or specific ICE inhibitors,
respectively, but suffer from side effects including colitis and
others (Reuter et al., 1996). Potential therapies exist that
involve the use of antibodies directed against the interface of
hIL-18 and hIL-18R or the use of recombinant hIL-18BP,
although these approaches face potential drawbacks in part
owing to immune rejection (Hamasaki et al., 2005). Identifi-
cation of small molecules targeting the hIL-18 surface and
disrupting the interaction between its receptors and IL-18BP
could potentially bridge the gap from current therapeutics to
the discovery of new therapeutics in the treatment of patho-
logical diseases attributed to hIL-18 dysregulation. An
important step in this process is obtaining crystals of apo hIL-
18 protein or of hIL-18 in complex with small-molecule inhi-
bitors. In this study, we employed surface-entropy reduction
(SER; Derewenda, 2004) to facilitate the crystallization of
hIL-18 in low ionic strength conditions.
2. Materials and methods
2.1. SER design, protein expression and purification
Mature hIL-18 was cloned into a modified pET vector as a
SUMO (small ubiquitin-like modifier) fusion protein with an
N-terminal 6His tag. We employed SER by targeting
exposed lysine and glutamate patches on the surface of
hIL-18, substituting these residues by alanine. The following
mutations were performed using standard overlapping PCR
(Shuldiner et al., 1990): hIL-18 mutant I (K139A, K140A,
E141A, E143A, L144A), mutant II (E128A, K129A, E130A,
K135A), mutant III (K67A, E69A, K70A, I71A), mutant IV
(mutant III plus E85A) and mutant V (P57R, K67A, E69A,
K70A, I71A, S105R).
We expressed the recombinant fusion proteins in trans-
formed Escherichia coli BL21 (DE3) Gold cells (Stratagene).
The cells were grown at 37C in Luria–Bertani (LB) broth
until the OD600 reached approximately 0.8–1.0, at which point
the temperature was lowered to 18C. Protein expression was
induced after 1 h with a final concentration of 1 mM isopropyl
-d-1-thiogalactopyranoside (IPTG). The cells were allowed
to continue to grow for an additional 18 h at 18C and were
then collected by centrifugation for 15 min at 5000g and stored
at 20C until use.
SUMO-hIL-18 mutants were purified at 4C or on ice using
a double Ni–nitrilotriacetic acid (Ni–NTA) procedure similar
to that described by Krumm et al. (2008). Cells collected as
above were suspended in buffer A (50 ml per litre of cultured
cells) consisting of 20 mM Tris–HCl pH 7.0, 500 mM NaCl,
10%(w/v) glycerol, 20 mM imidazole, 5 mM -mercapto-
ethanol (Sigma–Aldrich), 0.1 mM phenylmethanesulfonyl
fluoride (Sigma–Aldrich). His-tagged fusion proteins were
purified from the cells using high-pressure emulsification
(Emulsiflex-C5, Avestin Inc., Ottawa, Ontario, Canada). The
cell lysate was clarified by ultracentrifugation at 45 000g for
30 min and then batch-incubated for 4 h with 1 ml Ni–NTA
(Qiagen) per litre of cultured cells. The Ni–NTA slurry was
poured into a 20 ml disposable column (Bio-Rad), washed
with 20 column volumes of buffer A and the bound protein
was eluted with five column volumes of buffer A supple-
mented with 250 mM imidazole. The eluted fusion protein was
co-dialyzed with ULP1 (ubiquitin-like specific protease 1) at a
molar ratio of 100:1 (fusion:protease) in buffer A overnight to
remove the SUMO moiety, exposing the authentic hIL-18 N-
terminus (residue Tyr1). Cleaved protein mixtures were
subsequently passed through a second subtracting Ni–NTA
column and concentrated to approximately 1 mg ml1 using a
15 kDa molecular-weight cutoff centrifugal concentrator
(EMD Millipore). Concentrated hIL-18 mutants were further
purified by size-exclusion chromatography using an ÄKTA
purifier and a Superdex S200 16/300 column (GE Healthcare)
loaded with 500 ml sample at a flow rate of 0.4 ml min1
in 20 mM Tris–HCl pH 7.0, 100 mM NaCl, 5 mM
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-mercaptoethanol. All mutant proteins eluted as a single
monodisperse peak with an estimated molecular weight
corresponding to monomeric hIL-18 in solution. The best
fractions were concentrated as described above to saturation
and were then flash-frozen in liquid nitrogen and stored at
80C until use (Deng et al., 2004).
2.2. Crystallization and structure determination
When compared with the wild-type protein, the SER hIL-18
mutants typically showed reduced solubility and could only be
concentrated to 3–5 mg ml1, while the wild-type hIL-18 could
be concentrated to 6–8 mg ml1. Concentrated hIL-18
mutants were initially screened against an array of commer-
cially available sparse-matrix screens using the sitting-drop
vapor-diffusion method employing a 96-head Gryphon robot
(Art Robbins Instruments, USA). Crystals were optimized
around initial hits using a grid-screen matrix of PEG and
pH conditions. Mutant I crystallized in 47%(v/v) PEG 2000
monomethyl ether, 0.1 M HEPES pH 7.0, mutant III in
35%(v/v) PEG 3350, 0.1 M MES pH 6.5 and mutant V in
35%(v/v) PEG 3350, 0.1 M Tris pH 8.5, 0.1 M sodium acetate.
Mutants II and IV did not yield reproducible quality crystals.
Up to 5%(v/v) dimethyl sulfoxide (Sigma–Aldrich) was added
to the crystallization drops to improve the crystal quality. Prior
to data collection, the crystals were cryopotected by briefly
transferring them into a separate well containing mother
liquor supplemented with 20%(v/v) glycerol.
Data from single crystals of mutants I, III and V were
collected at beamline 19-ID at the Advanced Photon Source
(APS), Argonne National Laboratory using an ADSC
Quantum 315 detector system with 1 oscillation and 2–3 s
exposure. All images were indexed, integrated and scaled with
HKL-2000/HKL-3000 (Otwinowski & Minor, 1997). Initial
phases were determined by molecular replacement using
Phaser (McCoy et al., 2007) from the CCP4 suite (Winn et al.,
2011) with hIL-18 from PDB entry 3f62 (Krumm et al., 2008)
as a search model. PHENIX (Adams et al., 2010) and
REFMAC (Murshudov et al., 2011) were used for refinement
and Coot (Emsley et al., 2010) was used for iterative manual
model building. The translation, libration and screw-rotation
displacement (TLS) groups used in refinement were defined
by the TLMSD server (Painter & Merritt, 2006). The final
models have good refinement statistics as shown in Table 1.
All molecular-graphics figures were generated with PyMOL
(v.1.7.4; Schrödinger).
3. Results and discussion
The first structure of hIL-18 was solved by solution NMR and
other structures of hIL-18 have been determined either in
complex with its cognate receptor(s), IL-18BPs or with hIL-
18-specific antibodies (Kato et al., 2003; Krumm et al., 2008,
2012; Wei et al., 2014; Argiriadi et al., 2009; Tsutsumi et al.,
2014). Apo hIL-18 has been recalcitrant to crystallization.
Although the crystal structure of apo hIL-18 has only recently
been determined, the high ionic strength in the crystallization
condition is not readily amenable for binding with potential
ligands. In addition, the crystal packing buried the surface of
hIL-18 that is involved in binding both its primary receptor
(IL-18R) and IL-18BP, preventing the possibility of soaking
inhibitors into the existing crystals. We first attempted to
crystallize wild-type hIL-18 in low ionic strength conditions as
a basis for the design of small-molecule inhibitors targeting its
interface surface. After exhaustive attempts to crystallize
hIL-18, we were met without success and hIL-18 remained
recalcitrant to crystallization. To overcome this hurdle, we
employed the surface-entropy reduction (SER; Longenecker
et al., 2001; Derewenda, 2004) procedure by mutating spatially
clustered lysine and glutamate residues to alanine(s). We
visually inspected the structure of hIL-18 and mutated resi-
dues that were opposite the hIL-18–IL-18BP binding interface
before hIL-18 binary and ternary receptor complexes recently
became available. The identified residues are located at the
bottom of the -trefoil barrel opening on exposed loops
connecting individual -strands 5–6 (mutants III, IV and
V), 10–11 (mutant II) and 11–12 (mutant I) (Figs. 1b and
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Table 1
X-ray crystallographic data and refinement statistics.
Values in parentheses are for the highest resolution shell. The signal to noise








Beamline 19-ID, APS 19-ID, APS 19-ID, APS
Wavelength (Å) 0.97926 0.97929 0.97918
Space group P1 P212121 P212121
Unit-cell parameters
a (Å) 33.0 54.5 42.7
b (Å) 42.3 55.0 52.0
c (Å) 52.3 113.0 123.4
 () 77.8 90 90
 () 83.6 90 90







Total reflections 82848 172199 39780
Unique reflections 18429 24057 6953
Multiplicity 4.5 (3.3) 7.2 (6.9) 5.7 (4.2)
Completeness (%) 94.6 (81.6) 100 (100) 99.9 (98.3)
hI/(I)i 19.8 (2.1) 30.0 (3.2) 9.0 (1.6)
Rmerge† (%) 10.5 (49.0) 7.5 (56.2) 19.3 (88.5)
Refinement statistics
Resolution range used (Å) 50–1.91 50.0–2.00 33.0–2.85
No. of reflections used 17466 22784 6572
Rwork/Rfree‡ (%) 17.8/22.9 17.7/21.8 24.4/28.7
R.m.s.d., bond lengths (Å) 0.009 0.008 0.006
R.m.s.d., bond angles () 1.38 1.30 1.12
No. of atoms
Protein 2507 2483 2426
Water 103 16 0
Average B factor§ (Å2)
Protein 35.8 42.5 50.1
Water 40.4 147.4 0
Ramachandran plot
Preferred regions (%) 97.1 98.0 91.7
















hkl jFobsj. Rfree was calculated using 5% of data for mutants I
and III and 12.7% of data for mutant V. § Average B factors calculated using the
BAVERAGE program from the CCP4 suite.
1c; x2). The designed mutation sites were also confirmed with
the Surface Entropy Reduction prediction server (Goldschmidt
et al., 2007). The identified mutations resulted in the successful
crystallization of the three SER mutants that we have termed
mutants I, III and V (Table 1).
SER mutants I and III crystallized in distinct crystallization
conditions and in two different space groups. Mutant I crys-
tallized in space group P1 with two molecules in the asym-
metric unit forming a nonphysiological dimer in a tail-to-tail
orientation (Fig. 2a). The crystal contacts of mutant I involved
the SER loop between 11 and 12 on molecule A of a given
asymmetric unit forming hydrophobic contacts with its crys-
tallographic symmetry mate, with a BSA of 650 Å2 as analyzed
by the PISA server (Krissinel, 2010), and involved residues
Ser7 and Leu9 located on 1, Ile48 on 4 and Asn87 located
on the extended loop connecting 7 and 8 (Figs. 2b and 2c).
Mutant III crystallized in space group P212121 with two
molecules in the asymmetric unit forming a side-to-side
homodimer in an opposing orientation to each other (one
molecule facing up and the other facing down; Fig. 3a). The
mutant III SER loop between 5 and 6 was also involved in
crystal contacts between the two molecules in the asymmetric
research communications
714 Krumm et al.  Interleukin-18 Acta Cryst. (2015). F71, 710–717
Figure 2
Crystal packing of hIL-18 SER mutant I. (a) hIL-18 mutant I with two molecules in the asymmetric unit is shown in cyan and green enclosed by the red
outlined box. The view has been expanded to include symmetry-related molecules identifying crystal packing. Mutant I molecules are packed in a tail-to-
tail orientation within the asymmetric unit. The SER loop from one of the symmetry-related molecules is colored red and outlined in the cayenne-
colored box. (b) Surface representation of one mutant I molecule within the asymmetric unit (depicted similarly to as in Fig. 1a); the adjacent symmetry
mate positioned such as to occlude the binding interface is shown in cyan. (c) Enlarged view of van der Waals interactions between the SER loop and the
adjacent symmetry-mate molecule. (d) Enlarged view of the interactions at the interface between two overlapping molecules; hydrogen-bond
interactions are shown as red dotted lines.
unit via close contact interactions between the cysteine resi-
dues (Cys68) of the respective SER loops, forming an inter-
molecular disulfide bond despite the presence of reducing
conditions during protein purification. Hydrophobic inter-
actions were also observed between the two molecules of the
asymmetric unit, with a BSA of 546 Å2, and involved SER
loop residues Ala69 and Ala70 of molecule A interacting with
the aliphatic side chains of Ser7, Leu9 and the main chain of
Lys8 located on 1 of molecule B (Figs. 3b and 3c). In both the
mutant I and mutant III crystal structures the previously
identified interface surface patches on hIL-18 involved in
IL-18BP or hIL-18R binding were occluded by a crystallo-
graphic symmetry mate (Figs. 2b and 3b).
Further analysis of the SER mutant I and mutant III crystal
structures revealed a nearly symmetrical crystal-packing
interaction involving several binding-interface residues which
are also found in the recent apo hIL-18 structure (Kimura et
al., 2014; Tsutsumi et al., 2014). Surface residue Pro57 (site A)
of molecule A participates in van der Waals interactions with
the aliphatic side chains of Met60 (site B), Gln103, Ser105 and
Met113 (all in site C) of molecule B. Residues Pro57 and
Ser105 also participated in hydrogen-bonding interactions
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Figure 3
Crystal packing of hIL-18 SER mutant III. (a) Mutant III with two molecules in the asymmetric unit is shown in orange and yellow enclosed by the red
outlined box. The view has been expanded to include symmetry-related molecules identifying crystal packing. Mutant III molecules are packed in a side-
to-side orientation forming a homodimer with one molecule facing up and the other facing down relative to each other within the asymmetric unit. The
respective SER loops making contact with each other are colored in red and outlined in the cayenne-colored box. (b) Surface representation of one
mutant III molecule (depicted similarly to as in Fig. 1a); the adjacent symmetry mate positioned such as to occlude the binding interface is shown in
orange. (c) Enlarged view of van der Waals interactions between the SER loops within the asymmetric unit. Also identified is the intermolecular disulfide
bond between the SER loops. (d) Enlarged view of the interactions at the interface between the two molecules; hydrogen-bond interactions are shown as
red dotted lines.
between their main-chain O and N atoms, respectively
(Figs. 2d and 3d). We hypothesized that disrupting the Pro57
and Ser105 interactions would result in a different crystal
packing avoiding the unwanted homodimer structure. We
generated a new mutant, SER mutant V, by introducing
additional P57R and S105R mutations into mutant III. Mutant
V also crystallized in a high concentration of PEG 3350 in
space group P212121 similar to mutant III, but with signifi-
cantly different unit-cell parameters (Table 1).
Upon obtaining a good molecular-replacement solution, we
found that the P57R and S105R mutations indeed generated
new crystal lattice packing also containing two molecules
within the asymmetric unit. The crystal lattice packing displays
a head-to-side abutting orientation between molecule A of a
given asymmetric unit and molecule B of the adjacent asym-
metric unit (Figs. 4a and 4b). The two molecules within the
asymmetric unit are nearly parallel to each other, with a slight
twist relative to each other. Similar to mutant III, the mole-
cules form a side-to-side homodimer but with both molecules
in the asymmetric unit adopting the same orientation (facing
in the same direction relative to each other). Also similar to
mutant III, the SER loop between 5 and 6 is involved in
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Figure 4
Crystal packing of hIL-18 SER mutant V. (a) Mutant V with two molecules in the asymmetric unit is shown in magenta and blue enclosed by the red
outlined box. The view has been expanded to include symmetry-related molecules identifying crystal packing. Mutant V molecules are packed in a side-
to-side orientation almost parallel to each other, with both molecules facing in the same direction relative to each other within the asymmetric unit. The
SER loops from each molecule making contact with each other are colored in red and outlined in the cayenne-colored box. The molecules interact
predominantly through a disulfide bond between the two SER loops. (b) Surface representation of one mutant V molecule (depicted similarly to as in
Fig. 1a); an adjacent symmetry-related molecule positioned such as to allow a near completely open interface is shown in blue. (c) Enlarged view showing
van der Waals interactions between the SER loops. (d) Enlarged view of interactions at the interface between the two molecules; hydrogen-bond
interactions are shown as red dotted lines.
crystal contacts with a BSA of 386 Å2 between the two
molecules of the asymmetric unit via close contact interactions
between the cysteine residues (Cys68) of the respective SER
loops, forming an intermolecular disulfide bond. Additional
SER loop interactions involve van der Waals interactions
between C of Cys69 and the aliphatic side chain of Pro43
located on the loop connecting 4 and 5 (Fig. 4d). The side
chain of P57R of molecule A is involved in hydrogen bonding
and van der Waals interactions with residues Lys8, Leu9 and
Ser10 of 1 and the C-terminal residues Gln154 and Glu156 of
molecule B from an adjacent asymmetric unit (Fig. 4d). P57R
of molecule B and S105R from both molecules within the
given asymmetric unit are disordered and do not appear to
make any interactions with neighboring molecules. In this
crystal-packing pattern, the targeted hIL-18 surface on one
molecule is mostly open, while more than 50% of the surface
on the other molecule is also open and exposed (Fig. 4b).
4. Conclusion
Through surface-entropy reduction and rational protein
design, we have successfully crystallized an otherwise recal-
citrant protein in low ionic strength conditions. The SER
mutated residues were found to be consistently involved in
crystal lattice contacts. Rational protein engineering of the
pliable interface of hIL-18 has enabled the crystallization of
this previously occluded interface preventing the identifica-
tion and design of inhibitors targeting the interface of hIL-18.
The opportunity now exists to further exploit the hIL-18
interface by providing a platform for structure-based drug
design.
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